Recent advances of IDH1 mutant inhibitor in cancer therapy
Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans. In recent years, mutations in IDH have been observed in several tumors, including glioma, acute myeloid leukemia, a...
Saved in:
Main Authors: | Wangqi Tian (Author), Weitong Zhang (Author), Yifan Wang (Author), Ruyi Jin (Author), Yuwei Wang (Author), Hui Guo (Author), Yuping Tang (Author), Xiaojun Yao (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations
by: Weitong Zhang, et al.
Published: (2024) -
Discovery of Novel IDH1 Inhibitor Through Comparative Structure-Based Virtual Screening
by: Yuwei Wang, et al.
Published: (2020) -
Harnessing natural product polysaccharides against lung cancer and revisit its novel mechanism
by: Wangqi Tian, et al.
Published: (2024) -
De novo design of mIDH1 inhibitors by integrating deep learning and molecular modeling
by: Dingkang Sun, et al.
Published: (2024) -
3D-QSAR, Molecular Docking, and MD Simulations of Anthraquinone Derivatives as PGAM1 Inhibitors
by: Yuwei Wang, et al.
Published: (2021)